A secondary analysis of the phase 3 KEYNOTE-716 trial evaluates whether adjuvant pembrolizumab alters the risk of subsequent cutaneous malignancies in patients with resected stage IIB or IIC melanoma, while...
Stay up to date with the evolving standards of breast cancer care — our new timeline snapshot highlights the most significant U.S. clinical guideline changes from 2024 to present, including updates from...
Based on findings from the phase 3 MajesTEC-3 trial, the FDA announced the approval of teclistamab (Tecvayli) plus daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma who...
The FDA has granted traditional approval for the use of encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for treatment-naïve adults with BRAF V600E–mutant metastatic...
The FDA has approved a chemotherapy-free combination of acalabrutinib and venetoclax for adults with previously untreated CLL or SLL, based on a randomized phase 3 trial demonstrating a progression-free...
The FDA has authorized a first-of-its-kind therapeutic device that delivers tumor-treating fields for adults with locally advanced pancreatic cancer. The approval offers a new non-invasive option to extend...
The FDA approval expands frontline treatment options for adults with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant, based on randomized trial data showing...
In a large global phase 3 trial, investigators evaluated whether adding the CD19-targeted monoclonal antibody tafasitamab to the established lenalidomide–rituximab regimen could improve outcomes for adults...
A pooled analysis of 4 MagnetisMM trials evaluated dosing strategies for elranatamab, a BCMA-CD3 bispecific antibody, to identify the optimal regimen that mitigates cytokine release syndrome in patients...
